CorMedix, Inc. announced that it has signed a commercial agreement with MKM Co-Pharma GmbH. CorMedix entered into this agreement while awaiting the outcome of its application in the European Union for a CE mark for Neutrolin(R), a catheter lock solution. If approved for use in the EU, Neutrolin will be used for the prevention of catheter related bloodstream infection and maintenance of catheter patency in hemodialysis patients.